1. Market Research
  2. > Skin Cancer – Pipeline Review, H1 2013

Skin Cancer – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 327 pages

Skin Cancer – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Skin Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Cancer. Skin Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin Cancer.
- A review of the Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Skin Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Skin Cancer - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Skin Cancer Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Skin Cancer 15
Skin Cancer Therapeutics under Development by Companies 17
Skin Cancer Therapeutics under Investigation by Universities/Institutes 32
Late Stage Products 36
Comparative Analysis 36
Mid Clinical Stage Products 37
Comparative Analysis 37
Early Clinical Stage Products 38
Comparative Analysis 38
Discovery and Pre-Clinical Stage Products 39
Comparative Analysis 39
Skin Cancer Therapeutics - Products under Development by Companies 40
Skin Cancer Therapeutics - Products under Investigation by Universities/Institutes 62
Companies Involved in Skin Cancer Therapeutics Development 67
Bristol-Myers Squibb Company 67
Johnson and Johnson 68
F. Hoffmann-La Roche Ltd. 69
Vical Incorporated 70
Amgen Inc. 71
Sanofi-Aventis 72
AstraZeneca PLC 73
Eli Lilly and Company 74
Viralytics Ltd. 75
GlaxoSmithKline plc 76
Genentech, Inc. 77
Nektar Therapeutics 78
Inovio Biomedical Corporation 79
medac GmbH 80
Merck and Co., Inc. 81
Lentigen Corporation 82
Oxford BioMedica plc 83
Generex Biotechnology Corporation 84
Plexxikon Inc. 85
BioLineRx, Ltd. 86
Delcath Systems, Inc. 87
Amorfix Life Sciences Ltd. 88
Prolexys Pharmaceuticals, Inc. 89
Aposense Ltd. 90
Biofrontera AG 91
Histogen, Inc. 92
ZIOPHARM Oncology, Inc. 93
Millennium Pharmaceuticals, Inc. 94
Novartis AG 95
Aphios Corporation 96
Daewoong Pharmaceutical Co., Ltd. 97
Eisai Co., Ltd. 98
Laboratoires Pierre Fabre SA 99
LEO Pharma A/S 100
Ono Pharmaceutical Co., Ltd. 101
Pfizer Inc. 102
SuperGen, Inc. 103
Taiho Pharmaceutical Co., Ltd. 104
Takara Holdings Inc. 105
Teva Pharmaceutical Industries Limited 106
Hadasit Medical Research Services and Development Ltd 107
Exelixis, Inc. 108
Aduro BioTech 109
Celgene Corporation 110
Bayer AG 111
Incyte Corporation 112
Luitpold Pharmaceuticals, Inc. 113
Merck KGaA 114
4SC AG 115
Hana Biosciences, Inc. 116
Hemispherx Biopharma, Inc. 117
Celldex Therapeutics, Inc. 118
Anavex Life Sciences Corp. 119
Lorus Therapeutics Inc 120
Marshall Edwards, Inc. 121
AVAX Technologies, Inc. 122
Northwest Biotherapeutics, Inc. 123
Cleveland BioLabs, Inc. 124
Clinuvel Pharmaceuticals Limited 125
Oncolytics Biotech Inc. 126
Oncothyreon Inc 127
Compugen Ltd. 128
Osta Biotechnologies Inc. 129
Patrys Limited 130
Curis, Inc. 131
La Jolla Pharmaceutical Company 132
Tolerx, Inc. 133
Progen Pharmaceuticals Limited 134
Green Cross Corporation 135
MOLOGEN AG 136
Innocell Corporation 137
Provectus Pharmaceuticals, Inc. 138
Synta Pharmaceuticals Corp. 139
Summit Corporation plc 140
BioAlliance Pharma SA 141
Rexahn Pharmaceuticals, Inc. 142
PCI Biotech AS 143
Scancell Holdings Plc 144
MabVax Therapeutics, Inc. 145
Antigen Express, Inc. 146
Morphotek, Inc. 147
Cancer Research Technology Limited 148
Digna Biotech, S.L. 149
Oryzon 150
Antisense Pharma GmbH 151
Colby Pharmaceutical Company 152
Aurigene Discovery Technologies Limited 153
DNA Therapeutics S.A. 154
Ambit Biosciences Corporation 155
Philogen S.p.A. 156
siRNAsense AS 157
Hutchison MediPharma Limited 158
Crusade Laboratories Limited 159
Curacyte AG 160
BioNumerik Pharmaceuticals, Inc. 161
Cytheris SA 162
Altor BioScience Corporation 163
Alethia Biotherapeutics Inc. 164
NormOxys, Inc. 165
Telormedix SA 166
Hawthorn Pharmaceuticals, Inc. 167
MacroGenics, Inc. 168
PDS Biotechnology Corporation 169
AlphaVax, Inc. 170
Azaya Therapeutics, Inc. 171
Iconic Therapeutics, Inc. 172
Deciphera Pharmaceuticals, LLC 173
Affichem 174
Jennerex Biotherapeutics, Inc. 175
Axelar AB 176
Cornerstone Pharmaceuticals, Inc. 177
Pharminox Limited 178
Immutep S.A. 179
Innogene Kalbiotech Pte Ltd. 180
NovaLead Pharma Pvt. Ltd. 181
Omeros Corporation 182
Welichem Biotech Inc. 183
Vaccinogen, Inc. 184
Oncolys BioPharma Inc. 185
APEIRON Biologics AG 186
TSD Japan, Inc. 187
Immunocore Limited. 188
NewLink Genetics Corporation 189
SBI Biotech Co., Ltd. 190
BT PHARMA 191
InteRNA Technologies B.V. 192
PharmaMar, S.A. 193
Avir Green Hills Biotechnology AG 194
TVAX Biomedical, LLC 195
Biovista Inc. 196
AmpliMed Corporation 197
AB Science 198
Cannabis Science, Inc. 199
CureTech Ltd. 200
Genelux Corporation 201
WntResearch AB 202
Nereus Pharmaceuticals, Inc. 203
Viventia Biotechnologies Inc. 204
Lytix Biopharma AS 205
Medisyn Technologies, Inc. 206
Oncovir, Inc. 207
Moberg Derma AB 208
Archer Biosciences, Inc 209
ImmuneRegen BioSciences, Inc. 210
Life Science Pharmaceuticals, Incorporated 211
AIMM Therapeutics B.V. 212
Cancer Therapeutics CRC Pty Ltd 213
Targa Therapeutics Corp. 214
BioLife Science Forschungs- und Entwicklungsges. m. b. H. 215
Cytavis Biopharma GmbH 216
Bioo Therapeutics 217
Molecular Templates Inc. 218
GENEXTRA S.p.A. 219
n.v. BRUCELLS s.a. 220
KAEL-GemVax 221
Pacific Northwest Biotechnology, LLC 222
PepTx, Inc. 223
NAL Pharmaceuticals Ltd. 224
Polaris Group 225
Neumedicines Inc. 226
ToleroTech Inc. 227
ISA Pharmaceuticals B.V. 228
Gradalis Inc. 229
SentoClone AB 230
Lipotek Pty Ltd 231
Tocagen Inc 232
Advancell 233
Skin Cancer - Therapeutics Assessment 234
Assessment by Monotherapy Products 234
Assessment by Combination Products 235
Assessment by Route of Administration 236
Assessment by Molecule Type 239
Drug Profiles 242
velimogene aliplasmid - Drug Profile 242
vemurafenib - Drug Profile 244
paclitaxel albumin-bound - Drug Profile 246
talimogene laherparepvec - Drug Profile 248
MEK-162 - Drug Profile 250
M-Vax - Drug Profile 253
erismodegib - Drug Profile 255
Treosulfan - Drug Profile 257
GSK-2132231-A - Drug Profile 259
masitinib - Drug Profile 261
ubidecarenone - Drug Profile 263
nivolumab - Drug Profile 265
dabrafenib + trametinib - Drug Profile 268
cobimetinib + vemurafenib - Drug Profile 270
Contego - Drug Profile 272
POL-103-A - Drug Profile 273
Skin Cancer Therapeutics - Drug Profile Updates 274
Skin Cancer Therapeutics - Discontinued Products 292
Skin Cancer Therapeutics - Dormant Products 295
Skin Cancer - Product Development Milestones 315
Featured News and Press Releases 315
Appendix 324
Methodology 324
Coverage 324
Secondary Research 324
Primary Research 324
Expert Panel Validation 324
Contact Us 325
Disclaimer 325



List of Tables

Number of Products Under Development for Skin Cancer, H1 2013 17
Products under Development for Skin Cancer - Comparative Analysis, H1 2013 18
Number of Products under Development by Companies, H1 2013 20
Number of Products under Investigation by Universities/Institutes, H1 2013 35
Comparative Analysis by Late Stage Development, H1 2013 38
Comparative Analysis by Mid Clinical Stage Development, H1 2013 39
Comparative Analysis by Early Clinical Stage Development, H1 2013 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 41
Products under Development by Companies, H1 2013 42
Products under Investigation by Universities/Institutes, H1 2013 64
Bristol-Myers Squibb Company, H1 2013 69
Johnson and Johnson, H1 2013 70
F. Hoffmann-La Roche Ltd., H1 2013 71
Vical Incorporated, H1 2013 72
Amgen Inc., H1 2013 73
Sanofi-Aventis, H1 2013 74
AstraZeneca PLC, H1 2013 75
Eli Lilly and Company, H1 2013 76
Viralytics Ltd., H1 2013 77
GlaxoSmithKline plc, H1 2013 78
Genentech, Inc., H1 2013 79
Nektar Therapeutics, H1 2013 80
Inovio Biomedical Corporation, H1 2013 81
medac GmbH, H1 2013 82
Merck and Co., Inc., H1 2013 83
Lentigen Corporation, H1 2013 84
Oxford BioMedica plc, H1 2013 85
Generex Biotechnology Corporation, H1 2013 86
Plexxikon Inc., H1 2013 87
BioLineRx, Ltd., H1 2013 88
Delcath Systems, Inc., H1 2013 89
Amorfix Life Sciences Ltd., H1 2013 90
Prolexys Pharmaceuticals, Inc., H1 2013 91
Aposense Ltd., H1 2013 92
Biofrontera AG, H1 2013 93
Histogen, Inc., H1 2013 94
ZIOPHARM Oncology, Inc., H1 2013 95
Millennium Pharmaceuticals, Inc., H1 2013 96
Novartis AG, H1 2013 97
Aphios Corporation, H1 2013 98
Daewoong Pharmaceutical Co., Ltd., H1 2013 99
Eisai Co., Ltd., H1 2013 100
Laboratoires Pierre Fabre SA, H1 2013 101
LEO Pharma A/S, H1 2013 102
Ono Pharmaceutical Co., Ltd., H1 2013 103
Pfizer Inc., H1 2013 104
SuperGen, Inc., H1 2013 105
Taiho Pharmaceutical Co., Ltd., H1 2013 106
Takara Holdings Inc., H1 2013 107
Teva Pharmaceutical Industries Limited, H1 2013 108
Hadasit Medical Research Services and Development Ltd, H1 2013 109
Exelixis, Inc., H1 2013 110
Aduro BioTech, H1 2013 111
Celgene Corporation, H1 2013 112
Bayer AG, H1 2013 113
Incyte Corporation, H1 2013 114
Luitpold Pharmaceuticals, Inc., H1 2013 115
Merck KGaA, H1 2013 116
4SC AG, H1 2013 117
Hana Biosciences, Inc., H1 2013 118
Hemispherx Biopharma, Inc., H1 2013 119
Celldex Therapeutics, Inc., H1 2013 120
Anavex Life Sciences Corp., H1 2013 121
Lorus Therapeutics Inc, H1 2013 122
Marshall Edwards, Inc., H1 2013 123
AVAX Technologies, Inc., H1 2013 124
Northwest Biotherapeutics, Inc., H1 2013 125
Cleveland BioLabs, Inc., H1 2013 126
Clinuvel Pharmaceuticals Limited, H1 2013 127
Oncolytics Biotech Inc., H1 2013 128
Compugen Ltd., H1 2013 130
Osta Biotechnologies Inc., H1 2013 131
Patrys Limited, H1 2013 132
Curis, Inc., H1 2013 133
La Jolla Pharmaceutical Company, H1 2013 134
Tolerx, Inc., H1 2013 135
Progen Pharmaceuticals Limited, H1 2013 136
Green Cross Corporation, H1 2013 137
Innocell Corporation, H1 2013 139
Provectus Pharmaceuticals, Inc., H1 2013 140
Synta Pharmaceuticals Corp., H1 2013 141
Summit Corporation plc, H1 2013 142
Rexahn Pharmaceuticals, Inc., H1 2013 144
PCI Biotech AS, H1 2013 145
Scancell Holdings Plc, H1 2013 146
MabVax Therapeutics, Inc., H1 2013 147
Antigen Express, Inc., H1 2013 148
Morphotek, Inc., H1 2013 149
Cancer Research Technology Limited, H1 2013 150
Digna Biotech, S.L., H1 2013 151
Oryzon, H1 2013 152
Antisense Pharma GmbH, H1 2013 153
Colby Pharmaceutical Company, H1 2013 154
Aurigene Discovery Technologies Limited, H1 2013 155
DNA Therapeutics S.A., H1 2013 156
Ambit Biosciences Corporation, H1 2013 157
Philogen S.p.A., H1 2013 158
siRNAsense AS, H1 2013 159
Hutchison MediPharma Limited, H1 2013 160
Crusade Laboratories Limited, H1 2013 161
Curacyte AG, H1 2013 162
BioNumerik Pharmaceuticals, Inc., H1 2013 163
Cytheris SA, H1 2013 164
Altor BioScience Corporation, H1 2013 165
Alethia Biotherapeutics Inc., H1 2013 166
NormOxys, Inc., H1 2013 167
Telormedix SA, H1 2013 168
Hawthorn Pharmaceuticals, Inc., H1 2013 169
MacroGenics, Inc., H1 2013 170
PDS Biotechnology Corporation, H1 2013 171
AlphaVax, Inc., H1 2013 172
Azaya Therapeutics, Inc., H1 2013 173
Iconic Therapeutics, Inc., H1 2013 174
Deciphera Pharmaceuticals, LLC, H1 2013 175
Affichem, H1 2013 176
Jennerex Biotherapeutics, Inc., H1 2013 177
Axelar AB, H1 2013 178
Cornerstone Pharmaceuticals, Inc., H1 2013 179
Pharminox Limited, H1 2013 180
Innogene Kalbiotech Pte Ltd., H1 2013 182
NovaLead Pharma Pvt. Ltd., H1 2013 183
Omeros Corporation, H1 2013 184
Welichem Biotech Inc., H1 2013 185
Oncolys BioPharma Inc., H1 2013 187
APEIRON Biologics AG, H1 2013 188
Immunocore Limited., H1 2013 190
NewLink Genetics Corporation, H1 2013 191
SBI Biotech Co., Ltd., H1 2013 192
BT PHARMA, H1 2013 193
InteRNA Technologies B.V., H1 2013 194
PharmaMar, S.A., H1 2013 195
Avir Green Hills Biotechnology AG, H1 2013 196
TVAX Biomedical, LLC, H1 2013 197
Biovista Inc., H1 2013 198
AB Science, H1 2013 200
Cannabis Science, Inc., H1 2013 201
CureTech Ltd., H1 2013 202
Genelux Corporation, H1 2013 203
WntResearch AB, H1 2013 204
Nereus Pharmaceuticals, Inc., H1 2013 205
Viventia Biotechnologies Inc., H1 2013 206
Lytix Biopharma AS, H1 2013 207
Medisyn Technologies, Inc., H1 2013 208
Oncovir, Inc., H1 2013 209
Moberg Derma AB, H1 2013 210
ImmuneRegen BioSciences, Inc., H1 2013 212
Life Science Pharmaceuticals, Incorporated, H1 2013 213
AIMM Therapeutics B.V., H1 2013 214
Cancer Therapeutics CRC Pty Ltd, H1 2013 215
Targa Therapeutics Corp., H1 2013 216
BioLife Science Forschungs- und Entwicklungsges. m. b. H., H1 2013 217
Cytavis Biopharma GmbH, H1 2013 218
Bioo Therapeutics, H1 2013 219
Molecular Templates Inc., H1 2013 220
GENEXTRA S.p.A., H1 2013 221
n.v. BRUCELLS s.a., H1 2013 222
Pacific Northwest Biotechnology, LLC, H1 2013 224
PepTx, Inc., H1 2013 225
NAL Pharmaceuticals Ltd., H1 2013 226
Polaris Group, H1 2013 227
Neumedicines Inc., H1 2013 228
ToleroTech Inc., H1 2013 229
ISA Pharmaceuticals B.V., H1 2013 230
Gradalis Inc., H1 2013 231
SentoClone AB, H1 2013 232
Lipotek Pty Ltd, H1 2013 233
Tocagen Inc, H1 2013 234
Advancell, H1 2013 235
Assessment by Monotherapy Products, H1 2013 236
Assessment by Combination Products, H1 2013 237
Assessment by Stage and Route of Administration, H1 2013 240
Assessment by Stage and Molecule Type, H1 2013 243
Skin Cancer Therapeutics - Drug Profile Updates 276
Skin Cancer Therapeutics - Discontinued Products 294
Skin Cancer Therapeutics - Dormant Products 297



List of Figures

Number of Products under Development for Skin Cancer, H1 2013 17
Products under Development for Skin Cancer - Comparative Analysis, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Investigation by Universities/Institutes, H1 2013 34
Late Stage Products, H1 2013 38
Mid Clinical Stage Products, H1 2013 39
Early Clinical Stage Products, H1 2013 40
Discovery and Pre-Clinical Stage Products, H1 2013 41
Assessment by Monotherapy Products, H1 2013 236
Assessment by Combination Products, H1 2013 237
Assessment by Route of Administration, H1 2013 238
Assessment by Stage and Route of Administration, H1 2013 239
Assessment by Molecule Type, H1 2013 241
Assessment by Stage and Molecule Type, H1 2013 242

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.